A Comprehensive Review on Development of Nanomicellar-Based Topical Drug Delivery System for The Treatment of Uveitis

Uveitis is a sight-threatening inflammatory condition of the eye that poses significant treatment challenges due to the limited efficacy and potential side effects of conventional therapies. The advancement of innovative drug delivery systems offers significant potential for enhancing uveitis management by improving ocular drug bioavailability and reducing systemic side effects. Nanomicellar drug delivery systems have gained attention as a promising method for the topical treatment of uveitis. This review presents a summary of the current progress and recent developments in nanomicellar formulations for uveitis therapy. It discusses the characteristics and advantages of nanomicelles for ocular drug delivery, along with the pathophysiology of uveitis and the challenges associated with conventional treatment modalities. The review also highlights the formulation development techniques, optimization strategies, and efficacy and safety evaluation of nanomicellar-based drug delivery systems for uveitis. Furthermore, it explores the mechanisms of action of nanomicelles in targeting inflammatory pathways and modulating ocular immune responses while minimizing ocular toxicity. Challenges and future perspectives in the field, including stability issues, regulatory considerations, and potential applications in other ocular diseases, are also discussed. Overall, this review underscores the potential of nanomicellar-based topical drug delivery systems as innovative and effective therapeutic options for the treatment of uveitis, with the potential to improve patient outcomes as well as quality of life.